Valuation: ThermoGenesis Holdings, Inc.

Capitalization 11.09K 9.57K 8.93K 8.27K 15.25K 954K 17.11K 108K 40.74K 447K 41.61K 40.75K 1.65M P/E ratio 2022
-0.16x
P/E ratio 2023 -0.08x
Enterprise value 9.29M 8.02M 7.48M 6.93M 12.78M 800M 14.33M 90.65M 34.13M 374M 34.86M 34.14M 1.38B EV / Sales 2022
0.97x
EV / Sales 2023 1.18x
Free-Float
71.98%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
Current year 0
Extreme 0
0
1 year 0
Extreme 0
0.3
3 years 0
Extreme 0
16.65
5 years 0
Extreme 0
337.5
10 years 0
Extreme 0
7,020.01
More quotes
Manager TitleAgeSince
Chief Executive Officer 54 02/11/2016
Investor Relations Contact - -
Director TitleAgeSince
Chairman 54 02/11/2016
Director/Board Member - 13/07/2023
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-99.00%-.--% - - 15
+1.81%-2.47%-12.52%+4.03% 24.61B
-0.03%-2.52%-22.32%-25.31% 6.55B
+0.31%-.--%-.--%+68.37% 3.25B
-2.12%-3.29%-50.70%-50.40% 2.64B
+1.90%+6.14%+213.95% - 2.03B
-1.75%+1.43%+45.94%+89.54% 1.67B
-3.12%-3.91%+73.73%+220.30% 1.53B
-0.75%-3.23%-38.05%-21.53% 1.49B
+0.38%+1.60%+43.35%-19.09% 1.34B
Average -10.23%-0.66%+28.15%+33.24% 4.51B
Weighted average by Cap. +0.79%-2.00%+0.84%+10.47%
See all sector performances

Financials

2022 2023
Net sales 10.48M 9.05M 8.44M 7.82M 14.41M 902M 16.17M 102M 38.5M 422M 39.32M 38.51M 1.56B 9.44M 8.15M 7.6M 7.04M 12.98M 813M 14.57M 92.13M 34.69M 380M 35.43M 34.69M 1.4B
Net income -11.27M -9.72M -9.07M -8.4M -15.49M -970M -17.38M -110M -41.39M -454M -42.27M -41.4M -1.67B -17.98M -15.51M -14.47M -13.4M -24.71M -1.55B -27.73M -175M -66.02M -724M -67.42M -66.03M -2.67B
Net Debt 6.89M 5.94M 5.54M 5.14M 9.47M 593M 10.62M 67.19M 25.3M 277M 25.84M 25.3M 1.02B 9.28M 8.01M 7.47M 6.92M 12.76M 799M 14.32M 90.54M 34.09M 374M 34.82M 34.1M 1.38B
More financial data * Estimated data
Logo ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
Employees
25
More about the company
Date Price Change Volume

Delayed Quote OTC Markets, June 17, 2025 at 05:25 pm

More quotes

Quarterly revenue - Rate of surprise